EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy



Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy



Journal of Immunology 170(12): 6338-6347



CD8(+) CTL play important roles against malignancy in both active and passive immunotherapy. Nonetheless, the success of antitumor CTL responses may be improved by additional therapeutic modalities. Radiotherapy, which has a long-standing use in treating neoplastic disease, has been found to induce unique biologic alterations in cancer cells affecting Fas gene expression, which, consequently, may influence the overall lytic efficiency of CTL. Here, in a mouse adenocarcinoma cell model, we examined whether exposure of these tumor cells to sublethal doses of irradiation 1) enhances Fas expression, leading to more efficient CTL killing via Fas-dependent mechanisms in vitro; and 2) improves antitumor activity in vivo by adoptive transfer of these Ag-specific CTL. Treatment of carcinoembryonic Ag-expressing MC38 adenocarcinoma cells with irradiation (20 Gy) in vitro enhanced Fas expression at molecular, phenotypic, and functional levels. Furthermore, irradiation sensitized these targets to Ag-specific CTL killing via the Fas/Fas ligand pathway. We examined the effect of localized irradiation of s.c. growing tumors on the efficiency of CTL adoptive immunotherapy. Irradiation caused up-regulation of Fas by these tumor cells in situ, based on immunohistochemistry. Moreover, localized irradiation of the tumor significantly potentiated tumor rejection by these carcinoembryonic Ag-specific CTL. Overall, these results showed for the first time that 1) regulation of the Fas pathway in tumor cells by irradiation plays an important role in their sensitization to Ag-specific CTL; and 2) a combination regimen of tumor-targeted irradiation and CTL promotes more effective antitumor responses in vivo, which may have implications for the combination of immunotherapy and radiation therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 010885651

Download citation: RISBibTeXText

PMID: 12794167

DOI: 10.4049/jimmunol.170.12.6338



Related references

Low-dose irradiation of tumor cells upregulates Fas, enhances CTL lytic activity and CTL adoptive immunotherapy. Proceedings of the American Association for Cancer Research Annual Meeting 44: 887, July, 2003

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clinical Cancer Research 19(2): 393-403, 2013

Cyclophosphamide cy facilitated adoptive immunotherapy of a cy resistant tumor evidence that cy permits the expression of adoptive t cell mediated immunity by removing suppressor t cells rather than by reducing tumor burden. Immunology 65(1): 87-92, 1988

Adoptive immunotherapy of murine tumor using cultured syngeneic tumor-bearer-spleen cells. 1: Anti-tumor activity of tumor-bearer-spleen cells cultured with T cell growth factor (TCGF) and soluble tumor extract. Nihon Gan Chiryo Gakkai Shi 20(1): 31-39, 1985

Adoptive immunotherapy of murine tumor using cultured syngeneic tumor bearing spleen cells 1. anti tumor activity of tumor bearing spleen cells cultured with t cell growth factor and soluble tumor extract. Journal of Japan Society for Cancer Therapy 20(1): 31-39, 1985

IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cellular Immunology 179(1): 66-73, 1997

T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy. Oncotarget 7(14): 17565-17578, 2016

Recombinant huHsp47 is a novel selective immune-suppressant agent for adoptive immunotherapy It protects endothelial cells from damage by AI cells but does not cause reduction of tumor surveillance activity. Blood 92(10 SUPPL 1 PART 1-2): 341A, Nov 15, 1998

Adoptive tumor immunotherapy in mice as an adjunct to whole-body x-irradiation and chemotherapy. A review. Israel Journal of Medical Sciences 9(3): 350-365, 1973

Study on adoptive immunotherapy in patients with renal cell carcinoma. II. Plasmapheresis with adoptive immunotherapy using LAK cells and IL-2. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 81(7): 1058-1064, 1990

Adoptive immunotherapy as an adjunctive treatment to thoracic irradiation for pulmonary tumor deposits in mice. Cancer Research 49(18): 4979-4982, 1989

Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. II. Novel immunotherapy of B16 melanomas by local and systemic adoptive transfer. Journal of Immunology 138(6): 1979-1986, 1987

Tumor immune lymphocytes but not lymphokine activated killer lak cells increase the therapeutic activity of interleukin 2 il2 in a mouse model adjuvant adoptive immunotherapy. Proceedings of the American Association for Cancer Research Annual Meeting 30: 375, 1989

Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. Journal of Immunology 162(6): 3574-3582, 1999

The trafficking of infused, cultured tumor-draining lymph node cells into tissues is required for their continued proliferation and clinical activity during adoptive immunotherapy for metastatic cancer. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1158, July, 2003